Abstract
This major strategic analysis provides a detailed insight into the current and
future market for nucleic acid drug delivery technology.
Providing...
Critical analyses and competitive ratings for major specialist developers
Unique sales forecasts to 2015 for key current and new products utilising
nucleic acid drug delivery technologies A comprehensive examination of this
major drug delivery sector
Although the nucleic acid delivery market is still in its infancy there are
currently 1,300 clinical trials underway worldwide. The majority of these are
in early clinical development (c. 67%) with just over 2% on Phase II trials.
This indicates that relatively few nucleic acid candidates are likely to reach
the market in the short term but the potential of the sector is significant.
Our market analysis indicates that relatively few nucleic acid based products
have been approved for human prescription. Those that have, rely on novel
delivery technologies. The report estimates the nucleic acid market is worth
around US$65 million globally in 2007.
By 2015, nucleic acid products in development from ten key companies could
generate additional sales of around US$1.1 billion. These products utilise a
range of delivery platforms including viral to non-viral delivery systems and
cover gene therapies, gene agents and DNA vaccines for a variety of targets
including cancer, cardiovascular disease and infectious diseases.
Drivers and dampeners of growth
The future of nucleic acid based therapies and gene therapies hangs in the
balance whilst regulators and researchers weigh up the unmet clinical need for
curative/preventative therapies versus the safety issues (immunogenicity,
pathogenicity) associated with the delivery of some of these agents.
Whilst the majority of gene therapy trials under evaluation incorporate the
use of viral vectors there has been a shift in opinion in favour of non-viral
delivery. However, significant opportunities exist for future commercial
development within the pharmaceutical industry. These include:
- Development of new polymers and biopolymers that may be utilised in the
safe and efficient delivery of genetic material to host cells
- The development of viral and non-viral vectors that can be regulated and
incorporate high DNA payloads
- Targeted delivery of nucleic acid drugs to increase the specificity of
treatment
- Cost-effective production and application of safe and efficient vectors
for the delivery of nucleic acid-based therapies
- Identification and delivery of polygenic genes for the treatment of
multi-gene based diseases e.g. cancer
- Improvements in DNA vaccine delivery and immune stimulation
Which companies and products will succeed in the nucleic acid delivery sector?
What technical and regulatory hurdles must they overcome? This volume will
tell you!
View Cart
